7 days or less is a rapid aHUS diagnosis
A rapid diagnosis of aHUS in 7 days or less usually results in the patient having the best of health outcomes…
Eculizumab biosimilars available in Europe and USA
There are now licensed biosimilars to eculizumab available in Europe and also in the USA ( see previous article and further…
Choice of aHUS treatments
In making a choice aHUS patients’ preferences among treatments like eculizumab (and its biosimulars) , ravulizumab, crovalimab, and iptacopan it largely…
AIRG Suisse: Their aHUS Survey
Our aHUS Alliance Global Action team takes to heart our mission to “Inform. Connect. Collaborate” on ideas and initiatives across all…
Discontinuing complement inhibitor treatment
It is now just over 3 months since a discontinuing treatment decision making model was proposed to help aHUS patients make…
Why the kidney – blame the complosome?
Intracellular complement, or “complosome,” refers to the complement system’s activity within cells, a discovery that has significantly expanded the understanding of…
aHUS is likely at any time of year
More data about the time of year for aHUS was collected in the recent aHUS Global Poll to add to that…
Out with old in with the new- not quite just yet
On the 10th anniversary of international aHUS awareness day it is timely to raise awareness that the old term aHUS is…
What’s New in aHUS Research: SEPT 2024 Edition
Every year since the first aHUS Awareness Day on 24 Sept 2015 we’ve attempted to shine a spotlight on atypical HUS…